An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Markets enter the week on edge as Q2 earnings season kicks off with heavyweight banks and global blue chips. Investors will ...

On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough ...

HONG KONG] The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way ...

A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a ...

Nvidia reached another milestone in its rise to becoming one of the world’s most important companies: the first publicly traded company to reach a market value of $4 trillion. Nvidia and ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

In 2025, big changes in Washington have resulted in big changes on Wall Street. The investment outlook has been uncertain thanks to factors like tariffs and trade wars, inflation ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence individuals' weight loss after taking ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...